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Maternal mortality and morbidity is predominantly (40%) due to non-pregnancy related infections 
(HIV) in all South African provinces. Hypertension (14%) is the commonest direct cause of 
maternal deaths in pregnancy, of which 83% represents pre-eclampsia. Pre-eclampsia is unique to 
pregnancy and is characterised by new onset hypertension after 20 weeks of gestation in the 
presence of proteinuria. The renin-angiotensin-aldosterone system (RAAS) has a vital role in blood 
pressure development. The aim of the study is to examine the expression of circulating pro-renin 
(PR) and its receptor (P)RR in HIV associated normotensive pregnant and pre-eclamptic women.  
 
Following informed consent and expedited institutional ethics approval (BE 320/14) this study was 
conducted at the Optics and Imaging Centre, Doris Duke Medical Research Institute, UKZN. The 
study population (n=90) consisted of African women attending the ante-natal clinic at Prince 
Mshiyeni Memorial Hospital in Umlazi, Durban Metropolitan Area. There were 6 groups (n=90 
each), namely, control group of HIV positive and negative normotensive pregnant women (n=30) 
and an experimental group of pre-eclamptic women (n=60) stratified according to HIV positive 
and negative early (EOPE) and late (LOPE) onset pre-eclampsia. A quantitative sandwich enzyme 
immunoassay technique utilizing pro-renin Human ELISA and pro-renin receptor ELISA 
immunoassay kits were performed on plasma.  Intensity of the colour reaction was read 
spectrophotometrically at the wavelength (450 nm). The pro-renin and its receptor concentration 
levels were calculated using a standard curve derived from known concentrations. Shapiro-Wilk 
test, Mann-Whitney U test and Kruskal-Wallis test were used respectively to analyse data. 
 
The mean age ± SD of the total study population was 27±6 yrs with a significant difference in 
maternal age across all 6 study groups (p=0.004). There was a significant difference in maternal 
age (p=0.001) between HIV positive and negative groups regardless of pregnancy type. There was 
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no significant difference in maternal weight (p=0.153) between the HIV positive and negative 
groups regardless of pregnancy types. Maternal weight was higher in the pre-eclamptic groups 
compared to the normotensive group. In the LOPE HIV positive group the maternal weight was 
higher compared to the HIV negative group and also the EOPE HIV positive and negative groups. 
There was no significant difference in gestational age (p=0.504) between HIV positive and 
negative groups regardless of pregnancy type. Gestational age was higher in the normotensive and 
late onset pre-eclamptic groups compared to the early onset pre-eclamptic group. Also gestational 
age in the HIV positive EOPE group was higher than the HIV negative group. There was a 
significant difference in gravidity (p=0.003) between HIV positive and negative groups regardless 
of pregnancy type. There was a significant difference across all 6 study groups (p=0.024). 
Gravidity was higher in the normotensive HIV negative group compared to the EOPE and LOPE 
HIV negative groups.  
 
The mean PR ± SD of the study population was 3.98±2.01ng/ml.  PR was lower in the HIV 
positive group (3.86 ng/ml) compared to the HIV negative group (4.09 ng/ml). There was no 
significant difference in PR (p=0.599) between HIV positive vs the HIV negative group regardless 
of pregnancy type. There was no effect of pregnancy type (Normotensive vs EOPE vs LOPE; 
Normotensive vs PE) on PR levels (p=0.140; p=0.073) and amongst all 6 study groups (p=0.379). 
There was no difference in PR between the EOPE and LOPE groups (p=0.409) as well as 
normotensive vs LOPE (p=0.273).  However there was a significant difference between 
normotensive vs EOPE (p=0.039). 
 
The mean (P)RR ± SD of the total study population was 1.60±0.95ng/ml. There was no significant 
difference in (P)RR (p=0.541) between HIV positive and HIV negative groups regardless of the 
pregnancy type as well as across all pregnancy types (p=0.055). There was no difference between 
normotensive and pre-eclamptic (p=0.362). There was no difference between normotensive and 
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EOPE (p=0.074) and also between normotensive and LOPE (p=0.803).  However there was a 
significant difference between EOPE vs LOPE (p=0.019). 
 
Pearson correlation revealed no significant correlations between PR within each pregnancy type 
(normotensive, early onset and late onset pre-eclampsia).There was a positive correlation between 
diastolic blood pressure and (P)RR concentration in the late-onset pre-eclamptic group, which was 
statistically significant [rs=-0.380; p=0.046]. There were no significant correlation between 
maternal blood pressure and (P)RR in the normotensive pregnant and early onset pre-eclamptic 
groups. There was a positive correlation between PR concentration and the HIV negative late onset 
pre-eclamptic and HIV positive early onset pre-eclamptic group, which was statistically significant 
[rs=0.525; p=0.054]. A significant negative correlation occurred between PR concentration versus 
HIV positive late onset pre-eclamptic group and HIV positive early onset pre-eclamptic [rs=-0.643; 
p=0.018]. There were a significant positive correlation between (P)RR and diastolic blood pressure 
[rs = -0. 585; p=0.036]. 
 
A low (P)RR concentration will inhibit binding to the pro-renin molecule. Moreover, the pro-renin 
receptor represents an elegant concept to explain the existence of active pro-renin in vivo. This 
study provides a pathological protagonist for pro-renin receptor dysregulation in pre-eclampsia, a 
condition characterised with a paradoxical variation in renin/pro-renin and pro-renin receptor 
concentrations. Apart from the high blood pressure development, it may be associated with the 
ubiquitous proteinuria and the insufficient trophoblast invasion that characterises early onset pre-


























1.1 MATERNAL MORTALITY IN SOUTH AFRICA  
In South Africa, maternal mortality and morbidity for the triennium 2008-2010, is predominantly 
attributed to non-pregnancy related infections (40%; mainly pneumonia, TB and HIV). These non-
pregnancy infections are largely prevalent in ages between 25-40 years which relates to the HIV 
infection spread rate or pattern (SA Department of Health Report, 2012). Other factors that contribute 
to maternal deaths in South Africa, include hypertension, haemorrhage, ectopic pregnancy, 
miscarriage, pregnancy related sepsis and patient care in the hospitals. However, the major direct 
cause of maternal deaths is attributed to obstetric haemorrhage (14.1%) and hypertension (14%) (SA 
Department of Health Report, 2012).  
 
The two major causes of death in women of reproductive age globally is HIV and AIDS (19%) and 
complications (15%) related to childbearing (World Health Organisation Report, 2012). Globally, 
sub-Saharan Africa is the region with the highest maternal mortality rate (596 per 100000 live births) 
and where half of all maternal deaths occur (Hogan et al., 2010). In 2011, 90% of the total number of 
pregnant women with HIV were found to reside in sub-Saharan Africa (UNAIDS, 2012b). The region 
is home to 69% of the 34 million people living with HIV globally (UNAIDS, 2012a). In South Africa, 
maternal deaths due to non-obstetric causes predominate (40%) among women with HIV infection 
(SA Department of Health Report, 2012). KwaZulu-Natal is the epicentre of this HIV pandemic. The 
relationship between anti-retroviral treatment (ART) and pre-eclampsia is conflicting, with some 
studies reporting an increase in pre-eclampsia with ART and others showing no difference in rates of 
pre-eclampsia development between pregnant women living with HIV on ART and HIV-negative 
women (Kourtis et al., 2006; Suy et al., 2006; Hall et al., 2013). In South Africa of the 14% of 
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women that die from hypertension in pregnancy, 83% is attributed to a condition called pre-eclampsia 
(SA Saving Mothers Report, Department of Health, 2012). 
 
1.2 NORMAL PREGNANCY  
During normal pregnancy changes in the cardiovascular system occur i.e. an increase in heart rate, 
plasma volume, cardiac output increase and also the activation of the renin-angiotensin aldosterone 
system (RAAS). These changes are essential for meeting the blood and nutrient demands of the 
growing fetus (Tanbe and Khalil 2010; Seki, 2014). The first stage of pregnancy includes extravillous 
cytotrophoblast invasion of the uterine spiral arteries within the decidua and myometrium. The 
physiological transformation of the spiral artery includes replacement of the muscular wall of the 
spiral artery with a fibrinoid material. This converts the spiral artery from a narrow calibre vessel to a 
wide bore flaccid conduit that produces a ten-fold increase in luminal diameter hence increasing blood 
flow, oxygen partial pressure and nutrients required to meet the growing needs of the baby (Seki, 
2014). 
 
Normal pregnancy is allied with major vascular remodelling of both uterine and systemic circulation 
in order to meet the metabolic demands of the mother and the growing fetus. Vascular changes are 
dependent on the changes in activity of vascular mediators released from the endothelium, vascular 
smooth muscle and extracellular matrix (Mistry et al., 2013). The spiral arteries of the uterus in the 
gravid state and placental development are incorporated into the uteroplacental unit forming the 
decidual vessels, which are the afferent vessels of the maternal intervillous blood flow (Mistry et al., 
2013). If the nutritional demands of the fetus are not met, the growth of the fetus will be inadequate 





Pre-eclampsia is a hypertensive disorder unique to pregnancy in women diagnosed as sustained 
systolic blood pressure of greater than or equal to 140 mmHg and a diastolic blood pressure of 90 
mmHg taken on two occasions at least 6 hours apart with a new onset proteinuria (1+ on a urine 
dipstick analysis) or >30 mg/dl urine protein concentration at two intervals at least 4 hours apart.   
 
Pre-eclampsia has remained a significant public health threat in both developed and developing 
countries contributing to maternal and perinatal morbidity and mortality (McLure et al., 2009; Shah et 
al., 2009; WHO., 2011b). However, the impact of the disease is felt more severely in developing 
countries (Igberase and Ebeigbe, 2006), where, unlike other more prevalent causes of maternal 
mortality (such as haemorrhage and sepsis), medical interventions are ineffective due to late 
presentation of cases (Onakewhor and Gharoro, 2008; Moodley, 2011).  
 
In pre-eclampsia, the physiological transformation of the spiral arteries is believed to be limited to the 
decidua due to insufficient trophoblast invasion. This consequentially results in a deficient oxygen 
and nutrient supply to the fetus (Naicker et al., 2003; Berard et al., 2013).  
 
Although the aetiology of pre-eclampsia is uncertain (Tanbe and Khalil, 2010; Kuśmierska-Urban et 
al. 2013), a number of theories induced by lifestyle, genetic and biological factors have been put 
forward (Tanbe and Khalil, 2010; Mistry et al., 2013). Pre-eclampsia is mainly characterised by 
endothelial dysfunction, elevated inflammatory response and oxidative stress and activation of 
thrombosis (Mistry et al., 2013). Reduction of uteroplacental perfusion pressure and placental hypoxia 




Pre-eclampsia development emanates from the resultant hypoxic state of the placenta which is 
believed to release circulating bioactive factors such as hypoxia inducible growth factors and soluble 
fms-like tyrosine kinase that suppress pro-angiogenic factors with consequential maternal 
vasoconstriction of systemic arteries (Tanbe and Khalil 2010; Govender et al., 2013; Verdonk et al., 
2014). Treatment of pre-eclampsia is empirical; failure of the management of hypertension can lead to 
seizures, a condition referred to as eclampsia. There is no known cure for pre-eclampsia other than 
delivery of the placenta. 
 
1.4 RENIN-ANGIOTENSIN ALDOSTERONE SYSTEM (RAAS)  
The renin-angiotensin aldosterone system is an effective medium-term regulator of systemic blood 
pressure, fluid and electrolyte homeostasis. It is a cascade composed of various components that via a 
negative feedback becomes activated and functional (Seki, 2014). Components include pro-renin (a 
renin precursor), renin, angiotensinogen (AGT), angiotensin (Ang) I and II, and angiotensin-
converting enzyme (ACE). Renin and pro-renin are released by the juxtaglomerular cells and 
synthesised from intracellular granules. The kidney activates pro-renin and only 25% of activated pro-
renin is secreted as renin directly into circulation (Berard et al., 2013).  
 
Plasma renin carries out the conversion of angiotensinogen released by the liver to angiotensin I 
which has no known bioactivity (Berard et al., 2013).  Angiotensin I is subsequently converted to 
angiotensin II, by ACE found mainly in the lungs. Angiotensin II is a potent vaso-active peptide that 
causes blood vessels to constrict, resulting in elevated blood pressure (Verdonk  et al., 2014).  
 
Angiotensin II also stimulates the secretion of the hormone aldosterone from the adrenal cortex. 
Aldosterone causes the tubules of the kidneys to increase the reabsorption of sodium and water into 
the blood. This increases the volume of fluid in the body, which also results in increase in blood 
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pressure (Seki, 2014). This increase in blood pressure causes an increase in blood volume and cardiac 
contraction strength. It is the increase in cardiac output as a result of the increased blood volume and 
cardiac contractility which brings about the increase in blood pressure (Berard et al., 2013). Figure 1.1 















Table I.I: Source and function of the components of the Renin-Angiotensin Aldosterone System. 
Component  Source Functions 
Pro-renin receptor Cleavage from furin Activation of pro-renin and renin and 
acts as a V-ATPase 
Pro-renin Kidney and other extrarenal sites, 
constitutive release 
Conversion of angiotensinogen to 
angiotensin I (when bound to the pro-
renin receptor, functions as renin) 
Renin  Kidney, activated from pro-renin 
via proconvertase, cathepsin B  
Conversion of  angiotensinogen to 
angiotensin I 
Angiotensinogen Liver, adipose tissue (in obesity) Substrate for renin and pro-renin 
precursor of Ang I  
Ang I  
 
Angiotensinogen via renin or pro-
renin.  
Weak vasoconstrictor, pre-cursor of 
Ang II  
Ang II From angiotensin I via 
angiotensin converting enzyme 
Potent vasoconstrictor, stimulate the 




1.4.1 Placental pro-renin 
There are two different types of RAAS viz., circulatory and tissue specific RAAS. Tissue RAAS is 
regulated by the pro-renin receptor which also plays an important role in the assembly and functioning 
of H
+
-ATPase (Watanabe et al., 2012). The placenta is a vital organ for normal healthy pregnancy and 
fetal growth. There are two types of  placental RAAS, one occurring in the fetal placental 
compartment and the other in the maternal placental tissue (Kuśmierska-Urban et al., 2013; Yang et 
al., 2013). All the components of RAAS are found in the decidua and fetal placental tissues. In 
pregnancy, the high tissue RAAS activation arises from the high plasma pro-renin concentration (Jan 






Figure 1.2: Overview of pro-renin, active renin and (pro)renin receptors. Proteolytic activation 
involves irreversible removal of the pro-segment by enzymes, while non-proteolytic activation is the 
result of reversible removal of the prosegment sequence by acidic pH or low temperature (Ichihara et 
al., 2004). (P)RR has recently been attributed for the non-proteolytic activation of pro-renin through 
protein-protein interactions (Verdecchia et al., 2008). 
 
 
Pro-renin (PR) is known to be an inactive enzyme required for the production of active renin. The 
kidney produces both renin and pro-renin. However, a number of extrarenal tissues, including the 
adrenal, ovary, testis, placenta and retina can also produce pro-renin (Jan Danser et al., 2007; Berard 
et al., 2013). Other studies have indicated that the extrarenal sites of pro-renin production is important 
since the pro-renin levels in anephric subjects are approximately half the levels in normal subjects 
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(Morales et al., 2012). Pro-renin levels are normally higher than renin levels in plasma (Krop et al., 
2013). 
 
Activation of pro-renin occurs through the activity of cathepsin B or pro-convertase resulting in renin 
enzyme, via a proteolytic activation, or by a non-proteolytic activation that simply includes the 
binding of pro-renin to a pro-renin receptor (P)RR; (Fig 1.3; (Morales et al., 2012). These proteolytic 
activations occur exclusively in the kidney whilst the non-proteolytic activation is a reversible process 
which can be induced at low pH or low temperatures ( Nurun et al., 2007; Cruciat  et al., 2010). 
 
Inactivated pro-renin has a low intrinsic activity of 3% compared to the activity of fully activated pro-
renin (Krop et al., 2013).  Its intrinsic activity is accredited to a slight unfolding of its pro-segment 
(Morales et al., 2012). Human renin and pro-renin are glycosylated, and a variable proportion of renin 
and pro-renin have mannose-6-phosphate (M6P) residues that bind to the M6P–insulin-like growth 
factor II receptor (Jan Danser et al., 2007).  
 
Pro-renin was initially thought to be inactive; however, its secretion and possible functioning seems to 
be elevated in various pathologies (Berard et al., 2013; Seki 2014). The cause of this increase is 
unclear but reflects increased pro-renin gene expression and/or a decrease in pro-renin clearance 





Figure 1.3: The proteolytic and non-proteolytic activation of pro-renin (Seki, 2014). 
 
 
1.4.2. Pro-renin structure 
Pro-renin has an amino-terminal (43 amino acid sequence) pro-sequence (Ω-shaped) that covers the 
cleft between the 2 lobes of the enzyme.  This prevents access to the active site by its substrate, 
angiotensinogen (Morales et al., 2012).  This  amino acid sequence is located on the  N-terminal of a 
renin molecule (Morales et al., 2012). 
 
1.4.3 Pro-renin receptor 
The pro-renin receptor (P)RR was first identified in human mesangial cells and cloned (Cousin et al., 
2009). Pro-renin receptor is a multifunctional protein that is involved in the control of intracellular 
and extracellular pH via its interaction with the V-ATPase/MAP kinase signalling and Wnt/beta 




has an ability to activate pro-renin to form renin and then Ang I from AGT and enhances the affinity 
of renin for AGT (Cruciat et al., 2010). Oxidized AGT forms a sulfhydryl bridge (cys-18-cys 138) 
that has more than a 10-fold increase in affinity for (P)RR  bound renin (Nguyen and Muller, 2010). 
 
The pro-renin receptor is a newly identified regulator of RAAS that is essential for blood pressure and 
electrolyte balance. It is a cell surface receptor for pro-renin and renin. (P)RR binds renin and its 
inactive pro-renin which also triggers the phosphorylation of extracellular signal related protein 
kinase. This binding causes an increase in the catalytic activity of renin and causes the non-proteolytic 
activation of pro-renin that will lead to the generation of angiotensin I (Krop et al., 2013).  
 
Pro-renin receptor is largely located intra-cellularly with an intracellular vascular H-ATPase function. 
Pro-renin receptor is generated via the cleavage of the full length form by the enzyme furin or by 
ADAM19 in the golgi apparatus (Cruciat et al., 2010; Krop et al., 2013). Furin has an ubiquitous 
expression in adults, unlike other pro-convertases, however, it cannot be excluded that other pro-
convertases may also be involved in (P)RR processing (Cousin et al., 2009). Pro-renin receptor is 
detected within the Golgi apparatus, and is probably cleaved in the trans-Golgi to generate a soluble 
form (Cousin et al., 2009).  
 
The molecular forms of (P)RR  have been identified as a full-length form, a truncated transmembrane 
form that has the C terminal region (M8-9 fragment) and the most recently identified truncated 
soluble form that has the N-terminal region (Krop et al., 2013; Suzuki-Nakagawa et al., 2014). The C-
terminus region is said to be capable of the highly conserved cellular function, which might be related 
to the V-ATPase (Cousin et al., 2009). The extracellular domain is responsible for binding with renin 
and pro-renin, whereas the transmembrane and cytosolic domains are associated with V-ATPase 





Figure 1.4: The diagram showing the structure of (P)RR (top) and its association with V-ATPase 
(bottom). Abbreviation: SP, signal peptide; TM, transmembrane domain; and Cyt, cytoplasmic 
domain.  Adapted from Nishi and Forgac (2002). 
 
 
The pro-renin receptor is highly expressed in the brain, kidney, heart and placenta (Reudelhuber, 
2010). Pro-renin receptor is also expressed in mesangial cells, distal and collecting duct cells of the 
kidney and at a lower level in the liver, pancreas and human retina (Pringle et al., 2011). Experimental 
models suggest that the levels and activation of (P)RR increase in disease, especially in patients with 





Figure 1.5: Schematic diagram showing the processing of full length pro-renin receptor to soluble pro-
renin receptor and ATPase 6 associated protein (Ichihara et al., 2010). 
 
 
These different types of (P)RR can bind to renin and pro-renin and stimulate the activation of tissue 
RAAS. Pro-renin receptor over expression is associated with slow progression of hypertension and 
activation of tissue RAAS whilst the full length and truncated (P)RR forms are said to also pose a 
potential effect in causing the dysfunction of V-ATPase (Watanabe et al., 2012). 
 
The (P)RR gene is a highly conserved protein amongst a number of species. Its multi-species protein 
sequence comparison has revealed the existence of homologues to the human receptor in a variety of 
species, such as rat, mouse, chicken, frog, zebra fish, mosquito, drosophila, or even in species as 




Figure 1.6: The intracellular processing of (P)RR. Part of the receptor is cleaved in the trans-golgi to 
produce soluble (P)RR and the other part associates with V-ATPase and remains in the plasma 
membrane (Nguyen and Muller, 2010). 
 
 
In humans, the (P)RR  gene is located on the X chromosome at locus p11.4 (Nguyen and Muller, 
2010). Pro-renin receptor messenger RNA is 2034 base pairs long and there is no alternative splicing 
product present (Cruciat et al., 2010; Nguyen and Muller, 2010). The sequence alignment shows that 
the highest degree of homology encompasses the transmembrane and cytoplasmic regions of the 
protein corresponding to ATP6AP2, discovered in chromaffin granules and the M8.9, the fragment of 
(P)RR  that was reported to co- precipitate with the membrane sector V-ATPase (Cousin et al., 2009). 
 
In addition, the extracellular domain displays high amino acid sequence identity exclusively in 
invertebrates. Because RAAS emerged relatively late in evolution, the ATP6AP2 protein may have 






Figure 1.7: Binding of pro-renin receptor with renin and pro-renin with the post binding pathways 
(Reudelhuber, 2010). 
 
1.4.4 Pro-renin receptor structure 
Several studies have indicated that plasma membrane (P)RR occurs in a dimer form (Cousin et al., 
2009). However, the fact that (P)RR is detected as a 35-kDa band in Western blots indicates that 
(P)RR dimer on the cell membrane is not covalently bound.  
 
Pro-renin is a single peptide that is composed of a large extracellular domain, a single transmembrane 
domain and a short cytoplasmic domain from the N terminal to the C terminal (Cruciat et al., 2010; 





Figure 1.8: Structure of the pro-renin receptor (Ichihara and Keio, 2012). 
 
 
1.5 ASSOCIATION BETWEEN PRE-ECLAMPSIA, PRO-RENIN AND ITS RECEPTOR  
 
The role of pro-renin and its receptor in cells and in biological fluids include the activation of 
vacuolar proton-ATPase (intracellular pH enzyme) and a mitogen-activated protein kinase p44/42 
(that induces hypertension and glomerulosclerosis) (Berard et al., 2013). Pro-renin has pathological 
effect both inside and outside the renin-angiotensin system. Despite the cleavage of the pro-segment, 
pro-renin can gain the functional ability of renin and cause the production of angiotensin I which 
generates angiotensin II (Cruciat et al., 2010). This production reinforces the pro-fibrotic and pro-
inflammatory effect of angiotensin II (Pringle et al., 2011). 
 
 
Evidence that PR, (P)RR and renin is believed to play a direct role in vascular pathologies are: 
 elevations of circulating pro-renin is associated with diabetic microvascular disease 
(Luetscher et al., 1985). 
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 transgenic rats engineered to have a 400-fold increase in circulating pro-renin develop severe 
cardiac remodelling and renal lesions in the absence of hypertension (Veniant et al., 1996) 
raising the possibility that pro-renin is not only associated with tissue damage but that it may 
even be responsible for the damage by a mechanism that did not require Ang II generation.  
  (pro)renin receptor binds both pro-renin and renin with nanomolar affinity (Nabi et al., 
2006), causing an unfolding of pro-renin rendering it capable of contributing to local Ang II 
generation, and triggers several mitogen-activated protein kinase (MAPK) signalling 
pathways (Huang et al., 2006; Saris et al., 2006), on pro-renin and renin binding. Because this 
MAPK stimulation occurs in the presence of RAAS inhibitors, the triggered signalling 
appears to be independent of the angiotensin-generating enzymatic activity of pro-renin and 
renin (Feldt et al., 2008).  
 inhibiting the binding of renin and pro-renin to (P)RR with a competing peptide called handle 
region peptide (HRP; later also called pro-renin receptor blocker or (P)RRB; reduces cardiac 
hypertrophy and fibrosis in hypertensive rats without reducing blood pressure, diabetic 
glomerulosclerosis and proteinuria in rats and in mice in which the Ang II type 1 (AT1)α 
receptor had been inactivated (Ichihara et al., 2006a and b).  
 
This data has led to a model in which renin and pro-renin, through their interaction with (P)RR, 
stimulate a signal other than Ang II that promotes microvascular damage. Therefore, PR and (P)RR 
levels in pre-eclampsia requires evaluation.  New and more effective treatment developments such as 
blocking their action will prevent the characteristic vasoconstriction and endotheliosis that 







Aim: To examine the expression of circulating pro-renin (PR) and its receptor (P)RR in HIV 
associated normotensive pregnant and pre-eclamptic women. 
 
Objectives: 
 To compare the plasma expression of pro-renin and its receptor between: 
 normotensive and pre-eclamptic patients based on HIV infection 
 early-onset and late-onset HIV associated pre-eclamptic women 
 
Hypothesis:  
 The level of pro-renin and its receptor will remain the same across: 
 normotensive and pre-eclamptic pregnancies irrespective of the HIV status. 


































MATERIALS AND METHODS 
 
 
2.1 ETHICAL APPROVAL 
This study utilized plasma obtained retrospectively (BE 027/13), stored at the Optics and Imaging 
Centre, Doris Duke Medical Institute, College of Health Sciences, University of KwaZulu-Natal 
(UKZN) which received institutional ethical clearance (BE 320/14).  Informed consent was obtained 
from all patients participating in the study. 
 
2.2 STUDY POPULATION 
The study population consisted of pregnant normotensive and pre-eclamptic African women attending 
the ante-natal clinic at Prince Mshiyeni Memorial Hospital in the Umlazi, Durban metropolitan area. 
This is a district hospital servicing at least sixteen clinics in the Durban South region of KwaZulu-
Natal, South Africa. These patients were recruited by a research nurse who informed them about the 
procedures and their role in the study. Demographic profile of the patients was obtained from patient 
clinical/medical charts. 
 
2.2.1 Selection criteria 
Each group and subgroup was matched for gestational age, HIV status. All participants in our setting 
were on full HAART from 28 weeks of gestation with a single dose of nevirapine in labour if their 
CD4 count were less than 350 units.  
Inclusion criteria were: 
 Women who were 18 years of age and older. 
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 Pre-eclampsia was described as the new onset hypertension (BP>140/90 mmHg) and 
proteinuria (1+ on a dipstick) after 20 weeks of gestation. 
 HIV tests were conducted as a standard of care in the ante-natal clinic.  
 
Exclusion criteria for the pre-eclamptic group were: 
 Chorioamnionitis, chronic hypertension, eclampsia and placental related complications e.g., 
abruption placentae; 
 Intrauterine death, pre-gestational diabetes, gestational diabetes and chronic renal disease; 
 Systemic lupus erythematous, sickle cell disease and anti-phospholipid antibody syndrome; 
 Thyroid disease, cardiac disease and active asthma requiring medication during pregnancy; 
 Pre-existing seizure disorder and infection with human immunodeficiency virus. 
 
2.2.2 Sample size 
A sample size of 90 participants, determined by the institutional biostatistician, was considered 
sufficient to determine a statistical significance between the different variables being measured. The 
sample size for each group was decided from examination of previous studies.  
 
There were 6 groups, 15 samples per group. 
The sample was divided into  
a) control group (normotensive pregnant women; n=30); 
b) experimental group (early- and late-onset pre-eclamptic women; n=60). 
Both groups were further stratified according to HIV status. These groups are schematically 

















Figure 2.1: Schematic representation of study groups based on pregnancy type and HIV status 
 
2.3 METHODS 
2.3.1 Plasma separation from whole blood 
Prior to archival, plasma was separated from blood samples and stored at -80°C until required.  
 
2.3.2 The principle of enzyme-linked immunosorbent assay (ELISA) techniques  
The ELISA experiment was carried out according to the manufacturer’s instructions (Figure 2.2). The 


























 pro-renin human ELISA immunoassay kit (Abcam, Biocom Biotech, Johannesburg) 
 pro-renin receptor ELISA kit (Humor Diagnostic, Johannesburg).   
 
Both kits were based on a quantitative sandwich enzyme immunoassay technique.  Antigens from the 
sample are attached to a surface. Then, a specific antibody is applied over the surface so it can bind to 
the antigen. This antibody is linked to an enzyme, and, in the final step, a substance containing the 
enzyme's substrate is added. The subsequent reaction produces a detectable signal, most commonly a 
color change in the substrate. 
 
Performing an ELISA involves at least one antibody with specificity for a particular antigen. The 
sample with an unknown amount of antigen is immobilized on a solid microtiter plate specifically via 
capture by another antibody specific to the same antigen, in a "sandwich" ELISA. After the antigen is 
immobilized, the detection antibody is added, forming a complex with the antigen. The detection 
antibody can be covalently linked to an enzyme, or can itself be detected by a secondary antibody that 
is linked to an enzyme through bioconjugation. Between each step, the plate is typically washed with 
a mild detergent solution to remove any proteins or antibodies that are non-specifically bound. After 
the final wash step, the plate is developed by adding an enzymatic substrate to produce a visible 





Figure 2.2: Schematic representation of ELISA technique www.rndsystems.com. 
 
2.3.3 Procedure for the estimation of Pro-renin 
The standards, plasma samples and blanks, 100 µl each were added in duplicate to the wells and the 
plate was incubated on a shaker at 300 rpm for 30 minutes at room temperature. All wells were 
washed thrice with 300 µl of wash buffer. Pro-renin primary antibody, 100 µl was added to each well 
and the plate incubated on a shaker at 300 rpm for 30 minutes at room temperature. All wells were 
washed three times with 300 µl of 1x wash buffer and 100 µl of 1x HRP antibody was added to each 
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well. The plate incubated on a shaker at 300 rpm for 30 minutes at room temperature .and all wells 
were washed three times with 300 µl of 1x wash buffer. TMB substrate solution, 100 µl was added to 
each well and the plate was incubated at 300 rpm for 10 min at room temperature. All wells changed 
from colourless to different shades of blue, thereafter wells turned yellow when 1N HCL stop solution 
was added. The plate was measured at 450 nm within 30 minutes of adding the stop solution with the 
VersaMax™ ELISA Microplate Reader (Sunnyvale, CA 94089 USA).   
 
2.3.4 Procedure for the estimation of Pro-renin receptor 
Plasma samples were diluted (1:20) with EIA buffer. The standards, samples and reagent blank (EIA 
buffer), 100 µl each were added in duplicate to the wells and the plate was covered and incubated 
overnight at 4°C. All wells were washed four times with wash buffer, thereafter 100 µl of labelled 
antibody solution was added to each well. The plate was incubated for 60 min at 4°C and then washed 
five times with wash buffer. The chromogen (100 µl) was added to each well and the plate incubated 
for 30 min at room temperature in the dark. All wells turned blue and then yellow when 100 µl of stop 
solution was added to each well. The plate was measured at 450 nm within 30 minutes of adding the 
stop solution with the ELx800 Absorbance Reader (Winooski, VT 05404, USA). 
 
2.4 ANALYSES  
Absorbance was read at 450 nm.  The mean of duplicate standards and samples were calculated and a 
standard curve was plotted.  The concentration of pro-renin and its receptor in the samples under 





2.5 STATISTICAL ANALYSIS 
IBM SPSS Statistics Version 22 was used to analyze the data. Descriptive statistics for continuous 
data is presented as mean ± standard deviation. Both parametric and non-parametric tests were used to 
analyze clinical data. To determine the statistical differences between HIV positive and negative 
groups, pregnancy groups (normotensive versus early-onset pre-eclampsia versus late-onset pre-
eclampsia) and across all 6 study groups (normotensive HIV negative versus normotensive HIV 
positive versus early-onset pre-eclamptic HIV positive versus early-onset pre-eclamptic HIV negative 
versus late-onset HIV positive versus late-onset HIV negative) the Mann Whitney U and Kruskal-
Wallis tests were used. Spearman rank correlation was used to determine the correlation between 
prorenin and its precursor and specific maternal demographics. Differences at p<0.05 were considered 








































A total of 87 patients which comprised normotensive pregnant women (n=30; 34%) and pre-eclamptic 
(n=57; 66%) were studied. The pre-eclamptic group was further stratified into early-onset pre-
eclampsia (EOPE; n=29; 51%) and late-onset pre-eclampsia (LOPE; n=28; 49%). Each group 
included HIV positive (HIV+) and negative (HIV-) women. 
 
3.1 CLINICAL DEMOGRAPHICS ACROSS ALL STUDY COHORTS  
The clinical characteristics of the study participants are shown in Table 3.1.   
























25.7±6.4 27.1±5.5 26.7±5.7 31.4±5.2 22.9±5.5 29.5±6 
Systolic 
(mmHg) 
107.7±18.1 109.3±12.1 155.9±9.6 160.9±9.1 152.9±10.8 156.7±16.6 
Diastolic 
(mmHg) 








38.0±2.4 37.3±1.3 28.4±3.7 25.1±4.1 36.5±2.2 36.6±2.0 
Gravidity 1.9±3.7 2.4±1.5 1.9±1.3 2.8±1.7 1.5±0.8 2.5±0.9 
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3.1.1 Maternal age 
The mean age ± SD of the total study population was 27±6 yrs (Table 3.1). There was a significant 
difference in maternal age (U=560, p=0.001; Mann-Whitney U test) between HIV positive and 
negative groups regardless of pregnancy type (Figure 3.1). Maternal age in the HIV positive group 
(mean rank=53.18) was higher than the HIV negative group (mean rank=35.43).  
 
The distribution of maternal age was the same across pregnancy types [χ
2
(2)=3.946, p=0.139; 
Kruskal-Wallis test]. However, there was a significant difference in maternal age across all 6 study 
groups [χ
2
(5)=17.527, p=0.004]. Maternal age was higher in the HIV positive early- and late-onset 
pre-eclamptic groups compared to the HIV positive normotensive group and all HIV negative groups 

































3.1.2 Maternal blood pressure 
The mean systolic and diastolic blood pressure ± SD for each group is outlined in Table 3.1. The 
mean systolic and diastolic blood pressure ± SD of the total study population was 139.94 ± 26.34 and 
89.69 ± 20.00 mmHg. Based on HIV status there was no significant difference in systolic (U=874, 
p=0.546) and diastolic blood pressure (U=917.5, p=0.815).The  systolic [χ
2
(2)=59.37, p.<0.001] and 
diastolic blood pressures [χ
2
(2)=59.74, p<0.001] were significantly different in all pregnancy types 




(5)=62.08, p<0.001; Kruskal-Wallis test  
respectively]. The diastolic and systolic blood pressures were higher in the early onset (mean 
rank=62.36 and mean rank=63.24 respectively) and late onset (mean rank=55.52 and mean 
rank=54.52 respectively) pre-eclamptic groups compared to the normotensive group (mean 













3.1.3 Maternal weight 
The mean maternal weight ± SD for each group is outlined in Table 3.1. The mean maternal weight ± 
SD of the total study population was 72.09 ± 17.31 kg. There was no significant difference in 
maternal weight (U=777, p=0.153; Mann-Whitney U test) between the HIV positive and negative 
groups regardless of pregnancy types. Maternal weight was significantly different across pregnancy 
types [χ
2
(2)=11.386, p=0.003] and amongst all 6 study groups [χ
2
(2)=18.075, p=0.003; Mann-
Whitney U test; Table 3.1]. Maternal weight was higher in the pre-eclamptic groups (early onset mean 
rank=51.02 and late onset mean rank=50.21) compared to the normotensive group (mean 
rank=31.42). In the late onset pre-eclamptic HIV positive group the maternal weight was higher 
(mean rank=62.54) compared to the HIV negative group (mean rank=39.53) and also to the early 


































3.1.4 Gestational age 
The mean gestational age ± SD for each group is outlined in Table 3.1. The mean gestational age ± 
SD of the total study population was 33.68 ± 5.68 weeks. There was no significant difference in 
gestational age (U=866.5, p=0.504) between HIV positive and negative groups regardless of 
pregnancy type. The distribution of gestational age was different across all pregnancy types 
[χ
2
(2)=59.482, p<0.001] and all 6 study groups [χ
2
(2)=60.438, p<0.001; Kruskal-Wallis test]. 
Gestational age was higher in the normotensive (mean rank=62.90) and late onset pre-eclamptic 
(mean rank=53.75) groups compared to the early onset pre-eclamptic group (mean rank=15.03). Also 
gestational age in the HIV positive early onset pre-eclamptic group (mean rank=11.43) was higher 




































The mean gravidity ± SD for each group is outlined in Table 3.1. The mean gravidity ± SD of the total 
study population was 2±1. The Mann-Whitney U test showed that there was a significant difference in 
gravidity (U=606, p=0.003) between HIV positive and negative groups regardless of pregnancy type. 
The Kruskal-Wallis test showed that the distribution of gravidity was the same across all pregnancy 
types [χ
2
(2)=0.801, p=0.670], however there was a significant difference across all 6 study groups 
[χ
2
(2)=12.98, p=0.024]. Gravidity was higher in the normotensive HIV negative group (mean 
rank=42.50) compared to the early (mean rank=38.13) and late onset pre-eclamptic HIV negative 




































3.2 PRO-RENIN LEVELS  
 
The mean PR ± SD for each group is outlined in Table 3.1. The mean PR±SD of the study population 
was 3.98±2.01ng/ml.   
 
PR was lower in the HIV positive group (3.86 ng/ml) compared to the HIV negative group (4.09 
ng/ml). There was no significant difference in PR [t(83)=0.527, p=0.599] between HIV positive 
versus the HIV negative group regardless of pregnancy type. There was no effect of pregnancy type 
(Normotensive vs EOPE vs LOPE; Normotensive vs PE) on PR levels [F(2)=2.01, p=0.140; p=0.073] 
and amongst all 6 study groups [F(5)=1.08, p=0.379; Fig 3.5]. There was no difference in PR between 
the EOPE and LOPE groups (p=0.409) as well as normotensive vs LOPE (p=0.273; Fig 3.6).  











































3.3 PRO-RENIN RECEPTOR LEVELS  
The mean (P)RR ± SD for each group is outlined in Table 3.1. The mean (P)RR ± SD of the total 
study population was 1.60±0.95ng/ml.  
The Mann-Whitney U test showed that there was no significant difference in (P)RR (U=927873, 
p=0.541) between HIV positive (mean rank=42.29) and HIV negative (mean rank=46.60) groups 
regardless of the pregnancy type as well as across all pregnancy types [χ
2
(2)=5.803, p=0.055; 
Kruskal-Wallis test]. The levels were lower in the early onset pre-eclamptic group (mean rank=34.88) 
compared to the normotensive (mean rank=47.40) and late onset pre-eclamptic group (mean 
rank=49.80). However, there was no significant difference in (P)RR across all 6 study groups 
[χ
2
(5)=7.251, p=0.203; Fig 3.7]. There was no difference between normotensive and pre-eclamptic 
(p=0.362). There was no difference between normotensive and EOPE (p=0.074) and also between 
normotensive and LOPE (p=0.803).  However there was significant difference between EOPE vs 
LOPE (p=0.019; Fig 3.8). 
 
 

















































PR ng/ml 1.9±1.4 1.9±0.6 1.4±0.8 1.5±0.8 1.8±0.8 1.5±0.9 
(P)RR  
µg/ml 
1.83±0.95 1.83±1.18 1.51±0.77 1.06±1.11  1.66±0.88 1.65±0.62 






3.4 CORRELATION BETWEEN BLOOD PRESSURE AND PRO-RENIN WITHIN EACH 
PREGNANCY TYPE 
Pearson correlation revealed no significant correlations between PR within each pregnancy type 
(normotensive, early onset and late onset pre-eclampsia; Table 3.2). 
 
3.5 CORRELATION BETWEEN BLOOD PRESSURE AND PRO-RENIN RECEPTOR 
There was a positive correlation between diastolic blood pressure and (P)RR concentration in the late-
onset pre-eclamptic group, which was statistically significant [rs=-0.380; p=0.046; Spearman's rank 
order correlation; Table 3.2]. There were no significant correlation between maternal blood pressure 
and (P)RR in the normotensive pregnant and early onset pre-eclamptic groups.  
 
3.6 CORRELATION OF PR BETWEEN EACH STUDY GROUP 
There was a positive correlation between PR concentration and the HIV negative late onset pre-
eclamptic and HIV positive early onset pre-eclamptic group, which was statistically significant 
[rs=0.525; p=0.054 Spearman's rank-order correlation]. A significant negative correlation occurred 
between PR concentration versus HIV positive late onset pre-eclamptic group and HIV positive early 
onset pre-eclamptic [rs=-0.643; p=0.018; Spearman's rank-order correlation]. 
 
3.7 CORRELATION OF (P)RR WITHIN  STUDY GROUP 
There were a significant positive correlation between (P)RR and diastolic blood pressure [rs = 0. 585; 


















Normotensive rs(29) = -0.092,  
p=0.636 
rs(29) = -0.067,  
p=0.732 
rs(30) = -0.202,  
p=0.285 
rs(30) = -0.184,  
p=0.330 
EOPE rs(28) = 0.172,  
p=0.382 
rs(28) = 0.145, 
p=0.462 
rs(29) = -0.099,  
p=0.609 
rs(29) = -0.050,  
p=0.798 
LOPE rs(28) = -0.304,  
p = 0.116 
rs(28) = 0.050,  
p = 0.802 
rs(28) = 0.303,  
p = 0.117 
rs(28) = 0.380,  
p = 0.046 
Normotensive 
HIV-ve 
rs(14) = -0.161,  
p = 0.582 
rs(14) = -0.226,  
p = 0.437 
rs(15) = -0.344,  
p = 0.209 
rs(15) = -0.259,  
p = 0.351 
Normotensive 
HIV+ve 
rs(15) = 0.018,  
p = 0.950 
rs(15) = 0.116,  
p = 0.681 
rs(15) = 0.261,  
p = 0.348 
rs(15) = 0.023,  
p = 0.934 
EOPE 
HIV-ve 
rs(14) = 0.258,  
p = 0.371 
rs(14) = 0.485,  
p = 0.079 
rs(15) = -0.266,  
p = 0.338 
rs(15) = -0.474,  
p = 0.074 
EOPE 
HIV+ve 
rs(14) = 0.041,  
p = 0.889 
rs(14) = -0.061  
p = 0.836 
rs(14) = -0.029, 
p = 0.922 
rs(14) = 0.236,  
p = 0.416 
LOPE 
HIV-ve 
rs(15) = -0.393,  
p = 0.147 
rs(15) = 0.015,  
p = 0.957 
rs(15) = -0.503, 
 p = 0.056 
rs(15) = 0.104, 
 p = 0.711 
LOPE 
HIV+ve 
rs(13) = -0.217,  
p = 0.477 
rs(13) = -0.080,  
p = 0.794 
rs(13) = 0.122,  
p = 0.692 
rs(13) = 0.585,  
p = 0.036 




































The foremost source of women dying in pregnancy in Sub-Saharan Africa is HIV related. Pre-
eclampsia, is the commonest direct cause of maternal and neonatal morbidity and mortality in South 
Africa. The prevalence of HIV in our geographical area deems it a severe obstetric predicament. The 
co-location of both pathological conditions in pregnant women is frequent especially since KwaZulu-
Natal is the epicentre of the HIV pandemic. Hence study, into the HIV associated pre-eclampsia in 
our province is warranted.  
 
The aetiology of pre-eclampsia is enigmatic but it is fundamentally a pathology associated with a 
shallow trophoblast invasion compared to normal pregnancies (Naicker et al., 2003; Naicker et al., 
2013). Of the multifactorial aetiological agents underlying pre-eclampsia, the renin–angiotensin–
aldosterone system (RAAS) serves as the groundwork for the elevated blood pressure in pre-
eclampsia with a resultant series of events causing the resultant hypoxia. The relationship between 
pre-eclampsia, pro-renin and its receptor is poorly understood. 
 
Pre-eclampsia is characterised physiologically by plasma volume reduction, intravascular coagulation 
and potent vasoconstriction. Furthermore, compared with the surge in RAAS components in 
normotensive pregnancy, the circulating levels of renin, ANG I, ANG II, and aldosterone are much 
lower, yet with little erraticism of ACE levels (Shojaati et al., 2004). The hypothesis preferred by 
present researchers is that a gestational increase in plasma volume, viewed as a compensatory 
adaptation to support placental perfusion and fetal delivery, is vulnerable in pre-eclampsia due to a 
decrease in aldosterone, resulting in fluid insufficiency and ensuing placental ischemia (Gallery and 
Brown, 1987; Roberts and Cooper, 2001; Takeda et al., 2002). Therefore, the reduced circulating 
volume delimits placental blood supply, finally prompting a raised blood pressure during pre-
eclampsia. Due to our limited understanding of the underlying pathophysiology of pre-eclampsia, the 
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portrayal of the renin-aldosterone system in hypertensive pregnancy remains problematic. 
Furthermore, the renin-aldosterone system in both normotensive and hypertensive pregnancy may 
respond to physiologic signals such as changes in blood pressure and volume status, as well as to 
alterations in placental hormones such as estradiol and progesterone. 
 
 (P)RR binds both renin and its inactive precursor pro-renin. This binding initiates intracellular 
signalling that up-regulates the expression of profibrotic genes. Simultaneously, binding of renin to 
the (P)RR  increases its angiotensin I-generating activity, whereas binding of PR allows the ‘inactive' 
renin precursor to become fully enzymatically active. Therefore, the (P)RR  system reflects two 
functions, an angiotensin-independent function related to (P)RR induced intracellular signalling and 
its downstream effects and an angiotensin-dependent function related to the increased catalytic 
activity of receptor-bound PR (Nguyen  and Danser, 2008; Nguyen, 2011; Cao and Feng, 2013).  
 
In this study, there was a significant difference in maternal age across all study groups (p<0.004). The 
overall mean age of the study population was 27± 6 yrs, however one must be cognisant that an 
exclusion factor for this study was maternal age below 18 yrs. Nevertheless, the maternal age of our 
study population is in keeping with the global trend to delay first pregnancy (Johnson and Tough, 
2012). Progressive maternal age is a risk factor for low birth weight (Jolly et al., 2000; 
www.sciencedaily.com), preterm delivery (Aldous and Edmonson, 1993), placenta previa (Williams 
and Mittendorf, 1993), and admission of infants to special care facilities (Berkowitz and LaSala, 
1990). In this study, we also observed a significant difference in maternal age between the HIV 
positive and HIV negative cohorts (p<0.001). This may be incidental or linked to the fact that HIV is 
endemic to KwaZulu-Natal, as it is the global epicentre of the HIV pandemic. However our data is 
consistent with that of Mitqitti et al., (2008) who showed that maternal HIV positive status, young 
maternal age and gestational age were significant factors after adjusting for potential confounders. 
 
In our study, as expected (inclusion criteria) both the diastolic and the systolic blood pressure in the 
early and late onset pre-eclamptic groups were higher compared to the normotensive groups (p=0001 
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respectively).  Additionally, based on HIV status, there were no significant difference in systolic 
(p<0.546) and diastolic (p<0.815) pressure.  A previous study has indicated lower blood pressure 
(both systolic and diastolic) in HIV negative patients (Govender et al., 2014).  In contrast, studies by 
Gazzaruso et al., (2003) have linked the development of high blood pressure with HIV infection. 
 
In this study, maternal weight was higher in the pre-eclamptic group compared to the normotensive 
groups.  We also observed no significant difference in maternal weight between the HIV infected and 
uninfected groups (p=0.153).  The amount of weight gained during pregnancy can affect the 
immediate and future health of a woman and her infant. Evidence indicates relationships between 
extreme gestational weight gain and increased birth weight and postpartum weight retention but also 
between insufficient weight gain and decreased birth weight (Siega-Riz et al., 2009). 
 
In our study, gestational age was higher in the normotensive group compared to the pre-eclamptic 
groups (p=0.001), with gestational age been the lowest in the early onset group. Studies have shown 
that the risk of pre-eclampsia re-occurrence increases with earlier gestational age at the first delivery 
complicated by pre-eclampsia and with increasing maternal body mass index (Mostello et al., 2008). 
Additionally, we report no significant difference in gestational age (p=0.504) between HIV infected 
and non-infected groups in our study.  However the latter finding is directly in contrast with that of 
Mitgitti et al., (2008) who showed that gestational age correlated with maternal HIV positive status 
after adjusting for potential confounders. 
 
Pre-eclampsia is also considered a significant higher risk for low birth weight babies (Brand and 
Milder, 2013; Society for Maternal-Fetal Medicine, 2015). In our study gestational age was higher in 
the normotensive group compared to the pre-eclamptic groups (p=0.000) and this may be correlated 
with the low birth weight of infants. Supporting our data are numerous studies from Africa that show 
HIV-infected pregnant women are at increased risk of delivering low birth weight infants, of preterm 




Different types of hypertension in pregnancy have different profiles of plasma renin and pro-renin 
concentration in relation to development of pre-eclampsia (de León et al., 2001). In our study there 
were no difference in PR across all study groups (p=0.379) and between HIV positive versus the HIV 
negative group (p=0.599) regardless of pregnancy type. There was a positive correlation between PR 
concentration and the HIV negative late onset pre-eclamptic and HIV positive early onset pre-
eclamptic group, which was statistically significant (p=0.054). A significant negative correlation 
occurred between PR concentration versus HIV positive late onset pre-eclamptic group and HIV 
positive early onset pre-eclamptic [r=-0.643; p=0.018]. 
 
Additionally, with regards to PR versus pregnancy type in this study there was no difference in PR 
between the EOPE and LOPE groups (p=0.409) as well as normotensive vs LOPE (p=0.273).  
However there was a significant difference between normotensive vs EOPE (p=0.039). 
 
In this study we report decreased PR levels in EOPE.  These results are in contrast to that of Itskovitz 
et al., (1992b) however, they correspond to the gestational period. Early onset pre-eclampsia is 
preceded by trophoblast invasion and irregular placentation and poor angiogenesis occurring early in 
pregnancy. Strongly increased angiotensin II type 1 (AT1) receptor levels have been found in pre-
eclampsia (Herse et al., 2007). Likewise, microalbuminuria is known to be related with the pre-
eclampsia development. We speculate that the alteration in the renin–angiotensin system observed in 
the current study reflect maternal susceptibility emanating early in gestation from defective 
placentation. 
 
In pre-eclampsia, plasma renin activity and concentration and plasma angiotensin II and aldosterone 
concentrations are reduced compared to normal pregnancy. Plasma renin concentration is (two fold) 
greater in pre-eclampsia than normal pregnancy. Renin levels, remains stable throughout gestation 
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even during the third trimester of hypertensive pregnancy (Elsheikh et al., 2001). Plasma renin is said 
to increase 10 fold during pregnancy (Itskovitz et al., 1992a and b) whilst high plasma pro-renin 
levels, are derived from the ovaries (Derkx et al., 1987). It must be noted however, that our study 
reflects the precursor form viz., pro-renin levels obtained at term.  These results albeit displaying a 
trend are in contrast with the observation of higher PR levels in pre-eclamptic patients compared to 
normal pregnancies, the values being significantly low in the first and the third trimester (de Leon et 
al., 2001; Pringle et al., 2011; Pringle et al., 2015). Notably our results for PR stratified according to 
gestational age reflects a difference between normotensive and EOPE, which is characterised by 
inadequate placentation.  
 
In our study, (P)RR concentration was not significantly different between HIV positive and HIV 
negative groups (p=0.541) regardless of the pregnancy type as well as across all pregnancy types 
(p=0.055). There was no difference between normotensive and pre-eclamptic (p=0.362), specifically, 
there was no difference between normotensive and EOPE (p=0.074) and also between normotensive 
and LOPE (p=0.803).  However there was significant difference between EOPE vs LOPE (p=0.019). 
 
An increase in (P)RR and PR is usually associated with an increase in blood pressure (Batenburg and 
Jan Danser, 2012). (P)RR binds renin and the inactive pro-enzyme form of renin, pro-renin and this 
binding triggers the activation of the mitogen-activated protein kinase p42/p44 followed by up-
regulation of the expression of pro-fibrotic genes. In addition, pro-renin bound to (P)RR undergoes a 
conformational change and becomes catalytically active (Nguyen and Jan Danser et al., 2008). 
Additionally, binding to (P)RR increases the catalytic efficiency of renin 4-fold (Nguyen et al., 2002). 
The PR-(P)RR binding occurs under physiological conditions (37°C, pH=7.4) and only 1-2% of pro-
renin displays catalytic activity (Cousin et al., 2009). The binding of (P)RR  and PR has been shown 





(P)RR  has been put forward as a potential candidate/ or as a therapeutic target to optimize RAAS 
blockade in hypertension and end organ damage.  (P)RR activation plays a significant role in the 
development of end-organ damage in hypertension (Ichihara and Keio, 2012). However studies by 
Nguyen et al., (2011) refute this suggestion as their results in animal studies were disappointing and 
was not compelling enough to launch (P)RR  as key components in hypertension or in organ damage, 
although human studies have suggested a link between a polymorphism in the (P)RR  gene and blood 
pressure (Nguyen, 2011). More specifically, the stimulation of (P)RR initiates intracellular pathways 
allied to fibrosis (Gonzalez and Prieto, 2008; Gonzalez et al., 2014). 
 
In type II diabetes, the increase in PR correlates with the severity of proteinuria and retinopathy 
(Luetscher et al., 1985). Renin inhibitors may however block pro-renin receptors which modulate 
vaso-constriction, hypertrophy, atherosclerosis and fibrosis in target organs including kidney, heart 
and blood vessels (Jan Danser et al., 1997; Nguyen et al., 2002; Jan Danser, 2010). 
 
Angiotensin receptor blockers inhibit the interaction between angiotensin II and angiotensin AT1 
receptors, which modulate all the potential adverse effects of this peptide. Renin inhibition has 
potential for therapeutic benefits in conditions associated with high PRA (Laragh, 1992; Lin and 
Frishman, 1996). Aliskiren is the prototype of an oral renin inhibitor in vitro and in vivo (Wood et al., 
2003). PRA, angiotensin I and angiotensin II are depressed in a dose-dependent manner (Webb et al., 
1985; Nussberger et al., 2002). Blood pressure reduction is also dose-dependent and duration of 
action is more than 24 h (Webb et al., 1985; Oh et al. 2007). Aliskiren is the only orally active renin 
inhibitor that has progressed to phase III clinical trials. Although much more work needs to be done, 
optimal suppression of the RAS medicated by renin inhibition may unlock the potential for RAS 




Another archetypal role of (P)RR has been put forward. Whilst it is a contributor to the pathogenesis 
of blood pressure via the amplification of renin- or pro-renin-induced angiotensin (Ang) formation, a 
recent paradigm shift suggests a new role for (P)RR, separate from the renin-angiotensin system 
(RAAS), in contributing to cellular homeostasis. (P)RR binds renin and pro-renin with affinity in the 
nanomolar range (Nguyen et al., 2002; Nabi et al., 2006). Depending on the model, (P)RR activation 
may initiate diverse intracellular signaling pathways. In most types of cells, (P)RR  activation 
generates the mitogen activated protein kinases ERK1/2 phosphorylation, with resultant up regulation 
of the expression of pro-fibrotic genes such as transforming growth factor, plasminogen activator 
inhibitor type 1, collagens and fibronectin (Huang et al.,  2006; Sakoda et al., 2007; Feldt et al., 
2008).  These pro-fibrotic enhancing cytokines would decrease trophoblast cell migration with 
consequential deficient trophoblast invasion that characterises pre-eclampsia. Both (P)RR and PR 
have been found in the extravillous trophoblast cells, suggesting that they play a key role in 
trophoblast migration (Pringle et al., 2011). 
 
Specifically, (P)RR is thought to be crucial for vacuolar H+ -ATPase (V-ATPase) activity and acts as 
a connector between the V-ATPase and the Wnt signalling conduit (Müller et al., 2012; Nguyen., 
2012). The Wnt proteins are growth factors that signal via a complex formed of their primary receptor 
comprising seven transmembrane regions, and low-density lipoprotein receptor–related protein (LRP), 
a single-pass transmembrane protein (Nguyen et al., 2012). Wnt signaling is essential for normal 
embryo development. In adults, Wnt signaling is involved in cell proliferation, migration, polarity, 
and tissue repair and abnormal Wnt signaling is known to stimulate human degenerative diseases 
(Nguyen et al., 2012).  It is therefore plausible to hypothesize that a decrease in (P)RR levels would 
decrease Wnt signalling hence affect trophoblast cell proliferation and migration as is characteristic of 
pre-eclampsia. 
 
It must be noted that although the kidney is the foremost source of renin in the body, there are other 
tissues discharging pro-renin into the circulation (Jan Danser, 1998; Krop and Jan Danser, 2008). For 
instance, pregnant women have high plasma pro-renin levels, derived from the ovaries (Derkx et al., 
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1987). Pro-renin was discovered first in amniotic fluid. The reproductive organs, together with the 
adrenal, eye and submandibular gland are now well-accepted sites of extrarenal renin gene expression 
(Krop and Jan Danser, 2008). Our future investigation will include the immunostaining of (P)RR and 
PR in the placenta and placental bed of HIV associated normotensive and hypertensive pre-eclamptic 
women in an attempt to elucidate paracrine and/autocrine modes of production.   
 
The role of (P)RR in pre-eclampsia pathology requires the use of an antagonist of the receptor; and 
studies in knock-out mice to-date has not expressed the gene encoding for the receptor. The 
antagonist, is not yet ideal, and the total knock-out of the (P)RR is surprisingly for a component of the 
renin–angiotensin system, not possible (Zaman et al., 2002; Burcklé and Bader, 2006). The generation 
of (P)RR conditional knock-out mice is thus mandatory to further establish the role of (P)RR in 
disease.  
 
With the introduction of highly active antiretroviral therapy (HAART), the survival benefit from ARV 
therapy is indisputable.  Yet anti-retroviral treatment regimens are associated widely with HIV 
associated nephropathy (Szczech and Winston, 2004).  All HIV positive patients in this study were on 
anti-retroviral treatment as deemed by the Department of Health, South Africa hence they may have 
confounded the PR and (P)RR levels in our study. 
 
CONCLUSION 
This novel study demonstrates no significant difference in PR between HIV positive versus the HIV 
negative pregnancies regardless of pregnancy type. There was no difference in PR between the EOPE 
and LOPE groups as well as normotensive vs LOPE, however there was a significant difference 
between normotensive vs EOPE. This study also reports significant difference in (P)RR between HIV 
positive and HIV negative  groups regardless of the pregnancy type as well as across all pregnancy 
types, however, there was a significant difference between EOPE vs LOPE groups.. Both (P)RR and 
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PR probably play key roles in trophoblast migration in pregnancy and that the low levels shown in 
this study correlates with the defective invasion that occurs in EOPE. 
 
A low (P)RR concentration will inhibit binding to the pro-renin molecule. Moreover, the pro-renin 
receptor represents an elegant concept to explain the existence of active pro-renin in vivo. 
Additionally, this study provides a pathological protagonist for pro-renin receptor dysregulation in 
pre-eclampsia, a condition characterised with a paradoxical variation in renin/pro-renin and pro-renin 
receptor concentrations. Apart from the high blood pressure development, it may be associated with 
the ubiquitous proteinuria and the insufficient trophoblast invasion that characterises early onset pre-





RAAS enquiries have been proficient for more than a century. Yet, new constituents of the RAAS, in 
disease disorders such as pre-eclampsia are increasing its complexity. Understanding the binding of 
pro-renin to its receptor, and to mature renin is vital. Nonetheless, bearing in mind its 
pathophysiological contribution in hypertension, a more potent inhibitor that can preclude pro-renin 
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